Catamaran Bio provides preclinical data supporting CAT-248, a ready-made CD70 targeting CAR-NK cell therapy for the treatment of cancers expressing CD70 | BioSpace

2021-12-13 19:40:40 By : Mr. Chen Connor

– The data validated a new single-step NK cell engineering that uses a non-viral transposon system for CAR delivery combined with gene editing –

– Engineered CAR-NK cells show cytotoxicity to a variety of tumor cell lines –

CAMBRIDGE, MA--(BUSINESS WIRE)-- Catamaran Bio, Inc., a biotechnology company that has discovered chimeric antigen receptor (CAR)-NK cell therapies to treat cancer, today announced preclinical data These data prove its key capabilities and its TAILWINDTM platform has been applied to develop CAT-248, an allogeneic CD70 targeting CAR-NK cell therapy. The data proves the successful modification of CD70 CAR-NK cell therapy, which achieves cytotoxicity to various tumor cell lines in vitro. Using the integrated engineering and manufacturing capabilities of the TAILWIND platform, the data also showed the efficient non-viral delivery of CARs targeting CD70 and knocking out endogenous CD70 in a single engineering step.

The data supports the development of Catamaran’s joint leading CAR-NK cell therapy candidate drug CAT-248, which targets CD70, a tumor antigen that is highly expressed in certain types of cancer, including renal cell carcinoma and glial Tumors, pancreatic cancer and acute myeloid leukemia. The results will be announced at the 63rd Annual Meeting of the American Society of Hematology (ASH) in Atlanta on December 11-14, 2021.

"CD70 is a compelling target for several solid tumors and hematological malignancies with high unmet needs. We are happy to support the development of CAT-248 as an effective therapy for CD70-expressing cancers," said Doctor of Medicine, Master of Business Administration, CEO Alvin Shih said. Catamaran creature. "These data further establish our TAILWIND platform as an industry-leading, highly versatile and scalable CAR-NK cell therapy manufacturing platform, including complex products with multiple genome modifications."

Catamaran Bio’s Chief Scientific Officer, Dr. Vipin Suri, and MBA said: “Our ASH data demonstrates cutting-edge capabilities that are essential for tumor targeting design and the scalable manufacturing of CAR-NK cell therapies. “It’s worth noting that we have now Demonstrated a new single-step engineering method that can simultaneously use a non-viral transposon system for CAR delivery and combined with CRISPR editing for gene knockout. Using our TAILWIND platform, we have effectively integrated all the necessary characteristics, positioning our CAR-NK cells as an allogeneic, ready-made therapy for a variety of cancers, especially solid tumors. "

The data provided in the poster titled "Engineered CD70-directed CAR-NK Cells for the Treatment of Hematology and Solid Malignancies" describes experiments showing the key functions of the TAILWINDTM platform and the characteristics of CD70-targeted CAR-NK cells. Highlights of the poster include:

The research published in ASH was co-authored by Catamaran and his collaborators at the University of Minnesota. The poster display can be found on Catamaran's website.

About Catamaran Bio Catamaran Bio is developing new, ready-made chimeric antigen receptor (CAR)-NK cell therapies designed to treat a variety of cancers including solid tumors. Our proprietary capabilities allow us to take advantage of the natural anti-cancer properties of NK cells and use the power of synthetic biology and innovative non-viral cell engineering to enhance and adjust their effectiveness. We are using our TAILWIND™ platform, an integrated technology suite that specifically addresses the end-to-end method of engineering, processing and manufacturing NK cells, and rapidly advancing the pipeline of our CAR-NK cell treatment plan. Our team combines experienced biopharmaceutical leaders with founding scientists who are leaders in NK cell biology, engineering, manufacturing, and clinical applications. Catamaran is supported by leading financial and corporate investors, including SV Health Investors, Sofinnova Partners, Lightstone Ventures, Takeda Ventures, Astellas Venture Management and UMN Discovery Capital investment plans. For more information, please visit and follow us on LinkedIn and follow us on Twitter @CatamaranBio.

View the source version on

Catamaran: Mark Boshar, Chief Operating Officer 617-620-9709

Media: Kathryn Morris, Yates Networks 914-204-6412

View this press release online:

© 1985-2021 all rights reserved. Supported by Madgex work board software